Correction to: Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial
Abstract
Clinical Infectious Diseases 2023;77(6):937 © The Author(s) 2023. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons AttributionNonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [email protected] https://doi.org/10.1093/cid/ciad216 An error appeared in the 2 September 2022 issue of the journal (Dunne et al. “Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial.” Clin Infect Dis; 76(11): 66-77. https://doi.org/10.1093/cid/ciac738). In the “Discussion” section of the manuscript, several of the in-text citations are incorrect. The correct references should be listed as follows: Why would ASB occur sooner post-treatment among sulopenem-treated patients than among those treated with ciprofloxacin? One possible explanation is that ciprofloxacin has a greater impact on vaginal flora than a β-lactam such as sulopenem and that this in turn influences the rate of bladder recolonization. Similar observations have been made in 2 previous studies of uUTI and in a recent mouse model of UTI [18-20]. The area under the curve…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.